Literature DB >> 17478845

Should patient groups accept money from drug companies? Yes.

Alastair Kent1.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17478845      PMCID： PMC1865450          DOI： 10.1136/bmj.39185.461968.AD

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  1 in total

1.  Who's funding WHO?

Authors:  Michael Day
Journal:  BMJ       Date:  2007-02-17
  1 in total
  9 in total

1.  The illusion of invulnerability.

Authors:  Peter R Mansfield
Journal:  BMJ       Date:  2007-05-19

Review 2.  Moving from opacity to transparency in pharmaceutical policy.

Authors:  Irfan Dhalla; Andreas Laupacis
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

3.  Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.

Authors:  Susanna Leto di Priolo; Andras Fehervary; Phil Riggins; Kathy Redmond
Journal:  Patient       Date:  2012       Impact factor: 3.883

4.  Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries.

Authors:  Janneke Noordman; Liset van Dijk; Roland Friele
Journal:  BMC Health Serv Res       Date:  2010-02-22       Impact factor: 2.655

5.  Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.

Authors:  Susannah L Rose
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

6.  Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.

Authors:  Cinzia Colombo; Paola Mosconi; Walter Villani; Silvio Garattini
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

7.  EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Regulatory Processes.

Authors:  David Haerry; Cordula Landgraf; Kay Warner; Amy Hunter; Ingrid Klingmann; Matthew May; Wolf See
Journal:  Front Med (Lausanne)       Date:  2018-08-17

8.  Involving Patient Groups in Drug Research: A Systematic Review of Reasons.

Authors:  Christoph Rach; Jan Lukas; Regina Müller; Matthias Sendler; Peter Simon; Sabine Salloch
Journal:  Patient Prefer Adherence       Date:  2020-03-12       Impact factor: 2.711

9.  Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016).

Authors:  Piotr Ozieranski; Marcell Csanádi; Emily Rickard; Shai Mulinari
Journal:  BMJ Open       Date:  2020-09-19       Impact factor: 2.692
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.